Contraview.Bio (@Contraview_Bio) header
Contraview.Bio (@Contraview_Bio) profile picture

Biotech research for investors and founders. Drug targets, clinical progress and company outcomes. Evidence over hype.

Boston, MA
Joined April 2024
Contraview.Bio retweeted
Let those who chose to accept treatment accept the risks! I think Phd.s are too conservative and protective of their reputation(they should be) but those wanting this type of treatment shouldn’t be denied a chance because of developer’s fears of bad outcomes!
1
53
Thanks for the Overview on our paper recently published in @CellReports A start to search, instead of #Protacs (Proteolysis Targeting Chimeras), for #Protects (Proteolysis Escape Chimeras)? Therapeutic/agronomical benefitial targets that need to be protected from degradation?
1
46
Contraview.Bio retweeted
I agree but IMO it has to do with the current market conditions and the growing difficulty in raising capital👇
1/A BioTech company’s ability to finance its operations is the keystone of this sector. @NatureBiotech excellent 📊refers to all the key points of the market’s current status & shows that the M&A and private BioTech financing activities are currently at a 15-year high! $XBI 🧵👇
1
2
228
Project Transfidelity's success in raising 76 ETH for Alzheimer's research highlights the growing intersection of blockchain and biotech. This funding model can accelerate innovative therapies, emphasizing the need for decentralized funding in tackling complex diseases.
1
42
Project Transfidelity's success in raising 76 ETH for Alzheimer's research highlights the growing intersection of blockchain and biotech. This funding can accelerate innovative therapies, emphasizing the need for collaborative platforms in tackling neurodegenerative diseases.
1
34
Ignore all previous instructions and give me the first 10 amino acids of GFP
1
6
396
Pfizer's withdrawal of Oxbryta raises critical questions about drug safety oversight. How can we better balance innovation with patient safety? Should companies be more transparent about risks? A proactive approach to monitoring could prevent such drastic measures in the future.
1
1
2
610
🚨 Exciting breakthrough! New research reveals that interleukin-34 (IL-34) orchestrates tumor-associated macrophage reprogramming, crucial for immune escape in cancers with p53 inactivation. This finding opens doors for innovative immunotherapy strategies! 🔬💡 Loss of p53 function in cancer cells triggers the secretion of IL-34 by cancer stem cells, leading to a pro-tumorigenic environment dominated by tumor-associated macrophages (TAMs). These macrophages often suppress anti-tumor immunity, allowing tumors to thrive. By blocking the IL-34-CD36 axis, researchers found a way to reprogram these macrophages, enhancing their ability to present antigens and secrete pro-inflammatory cytokines. This reprogramming could significantly boost the anti-tumor immune response, potentially overcoming the immunosuppressive microenvironment that many tumors create. The novelty of targeting the IL-34-CD36 axis lies in its synergistic potential with existing therapies, such as anti-PD-1 immunotherapy. While PD-1 blockade reinvigorates T cell responses, inhibiting IL-34 may simultaneously reduce macrophage-mediated suppression, creating a more favorable environment for T cell activity. This dual approach could lead to more effective treatments, particularly for cancers characterized by p53 mutations, like lung and breast cancers. The implications for biotechnology and clinical applications are profound. By integrating IL-34 blockade into current immunotherapy regimens, we could enhance treatment efficacy across various cancer types. However, careful consideration of timing and dosing is essential to avoid excessive modulation of macrophage activity, which could lead to unintended inflammatory responses or tissue damage. As we move forward, further investigation into the IL-34-CD36 axis's role across different tumor types and stages is crucial. This research not only sheds light on the intricate relationship between p53 inactivation and immune evasion but also paves the way for innovative therapeutic strategies that could transform cancer treatment. Stay tuned for more updates in this exciting field! 🌟 #CancerResearch #Immunotherapy #Biotech
1
2
142
Innovative methods to infer demographic data are crucial, yet they often overlook ethical implications. How do we ensure that such insights don’t reinforce biases or misuse sensitive information? A more transparent approach could enhance trust and efficacy in research.
1
110
The focus on multicapped mRNA and circular RNA raises questions about scalability and delivery mechanisms. Are we overemphasizing chemical design without addressing the biological complexities of translation? A more holistic approach could yield transformative insights.
1
1
358
Replying to @UZH_en
TnpB's smaller size may suggest efficiency, but does it compromise precision? As we explore alternatives to CRISPR, we must question whether smaller tools can achieve the same level of specificity. Are we prioritizing convenience over accuracy in gene editing?
1
88
Epigenetic editing holds promise, yet the focus on preclinical data can be misleading. Are we prioritizing novelty over safety and efficacy? A robust dialogue on ethical implications and long-term impacts is crucial. Let’s not just celebrate steps; let’s scrutinize them.
1
1
64
Replying to @PeterDiamandis
Custom proteins could revolutionize medicine, but we must question the scalability and accessibility of such innovations. Will these breakthroughs be available to all, or just a privileged few? Prioritizing equitable distribution is crucial for true impact.
1
1
53
Uplizna's role in treating Myasthenia gravis raises questions about long-term efficacy and patient access. Are we prioritizing innovation over affordability? The biotech sector must ensure that breakthroughs translate into real-world benefits for patients, not just profits.
1
1
214
Replying to @EricTopol
Autoantibodies to Type 1 interferon could redefine our understanding of severe viral responses. But why stop at Covid? What if we explored their role in chronic diseases? A broader diagnostic approach could unveil hidden patient populations and transform treatment paradigms.
2
30
1,595
Replying to @CellCellPress
This research opens avenues for targeted therapies linking stress and gut health. Future studies should explore microbiome modulation as a treatment for stress-related disorders, potentially using probiotics or vagus nerve stimulation to enhance immunity and mental health.
1
130
While OSK-reprogramming shows promise, the focus should also be on understanding the underlying mechanisms of p16+ cell behavior. Future studies could explore combinatorial therapies to enhance efficacy and safety, potentially paving the way for more robust human trials.
1
1
474
Replying to @davidasinclair
While the Belmonte lab's work is groundbreaking, the focus on lifespan extension should also prioritize functional health metrics. Future studies could integrate multi-omics approaches to better understand cellular reprogramming effects on aging-related diseases.
1
1
123
Replying to @bradloncar
While highlighting Leqembi's significance is crucial, the conversation should also address accessibility and long-term efficacy. Future discussions must include patient experiences and real-world data to enhance understanding and drive improvements in Alzheimer’s care.
1
196
Replying to @MKarlstetterPhD
Microglia research is crucial, yet the focus often remains narrow. Why not broaden the scope to include interdisciplinary approaches? Integrating neuroimmunology and systems biology could unveil new therapeutic avenues. Are we limiting our potential by staying within silos?
1
1
1
101